RxDoctor Payments DataLook up a doctor →

James Strickland, MD

Clinical Cardiac Electrophysiology · The Woodlands, TXNPI 1235276411

Payments from drug & device makers

$319,871in general payments, 2019–2025

Across 694 payments — averaging $460.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$226K
  • Boston Scientific$66K
  • Biotronik Inc.$12K
  • Elutia, Inc.$10K
  • Biosense Webster, Inc.$2K
  • Impulse Dynamics (USA) Inc.$1K
  • plus $3K from 22 others

What the payments were for

  • Consulting fees$5,6006%
  • Speaking & faculty fees$63,62565%
  • Travel & lodging$3,2963%
  • Food & beverage$25,97826%
  • Other$330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$319,871 in reported general payments places this provider in the 85th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$149,347
Medicare patients
314
Services billed
1,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan142$128,416
EliquisApixaban97$72,925
XareltoRivaroxaban67$68,376
CorlanorIvabradine Hcl32$22,666
JardianceEmpagliflozin16$13,080
MultaqDronedarone Hcl16$12,605
Flecainide Acetate106$3,004
Metoprolol Succinate245$2,585
Diltiazem 24hr Er (Cd)Diltiazem Hcl50$1,565
Digoxin91$1,353
Amiodarone Hcl136$1,240
Metoprolol Tartrate160$1,023
Nifedipine ErNifedipine24$711
Losartan Potassium87$668
ClopidogrelClopidogrel Bisulfate76$622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$112$128,416142 claims
PfizerEliquis$72$72,92597 claims
Johnson & JohnsonXarelto$163$68,37667 claims
AmgenCorlanor$75$22,66632 claims
Boehringer IngelheimJardiance$79$13,08016 claims
Sanofi-aventis U.S. LLCMultaq$215$12,60516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →